This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Efficacy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • there is evidence that buproprion is effective in helping people to give up smoking - in one study at 12 months the abstinence rates were (1):
    • bupropion and nicotine replacement group - 35.5%
    • bupropion group - 30.3%
    • nicotine replacement therapy alone group - 16.4%
    • placebo - 15.3%

Of note regarding this trial data is that:

  • the abstinence rate was based on point prevalence of quitting (smoking status based on reported quitting at the end of the year) rather than the more rigorous outcome of sustained abstinence (quitting for the whole year following treatment) - using sustained abstinence then the quit rate in this trial was about 18% (2)
  • trial data from one trial has shown bupropion to be more effective than a nicotine patch (3) - however another unpublished randomised controlled trial did not (3)

A systematic review revealed that bupropion and notriptyline increase abstinence from smoking at >= 6 months (3).

Reference:

  1. NEJM (1999); 340: 685-91.
  2. PULSE (29/7/00), 28-9.
  3. Hughes JR et al (2003). Antidepressants for smoking cessation. Cochrane Database Syst Rev 2003;(2):CD0003

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.